查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1736518

2026 年至 2032 年成人疫苗市场（按疫苗、疫苗类型、技术、最终用户和地区划分）

Adult Vaccine Market By Vaccine, Vaccine Type, Technology, End-User, & Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格
简介目录

成人疫苗市场评估 - 2026-2032

流感、肝炎和带状疱疹等感染疾病的流行，以及政府为提高人们对疫苗重要性的认识而推出的项目，正在推动成人疫苗市场的扩张。本研究报告对全球成人疫苗市场进行了全面评估。预计2024年市场规模将超过172.7987亿美元，2032年将达到约277.5004亿美元。

此外，疫苗接种技术研究的不断增加和政府资金的增加使得市场在 2026-2032 年期间的复合年增长率达到 6.10%。

成人疫苗市场定义/概述

成人疫苗是专为18岁及以上人群设计的疫苗，用于预防感染疾病，并降低重症、併发症和病原体传播的风险。这些疫苗作为基础疫苗或加强疫苗接种，以维持儿童疫苗诱发的免疫力。

常见的成人疫苗包括流感疫苗、破伤风疫苗、白喉疫苗、百日咳疫苗、肺炎疫苗、带状疱疹疫苗、人类乳突病毒疫苗 (HPV)、甲型肝炎疫苗、B型肝炎疫苗、麻疹疫苗、腮腺炎疫苗、德国德国麻疹(MMR)、水痘疫苗、脑膜炎双球菌疫苗和C型肝炎疫苗。建议每年接种流感疫苗，以预防季节性流感病毒，特别针对老年人、孕妇、医护人员和患有慢性疾病的人等高风险族群。 Tdap 疫苗每 10 年接种一次加强针，以持续预防破伤风、白喉和百日咳。

建议65岁及以上成年人以及患有某些疾病的未满18岁人群接种肺炎球菌疫苗，以预防肺炎球菌引起的肺炎、脑膜炎和血液感染疾病。建议50岁以上成年人接种带状疱疹疫苗，以预防带状疱疹（一种由水痘带状疱疹病毒引起的疼痛性皮疹）。建议26岁以下成年人人类乳突病毒(HPV)疫苗，以预防子宫颈癌、肛门癌、其他癌症以及生殖器湿疣。

治疗和预防策略的进步，包括甲肝和B肝疫苗，对于控制丙肝病毒感染疾病和预防肝臟相关併发症至关重要。疫苗接种建议因年龄、健康状况、职业、旅游历史和其他因素而异，因此咨询您的医疗保健提供者或公共卫生部门，以确定适合每个人的疫苗接种时间表至关重要。

根据美国国家生物技术资讯中心 (NCBI) 的数据，美国和其他地区每年有许多成年人死于疫苗可预防的疾病。此外，美国疾病管制与预防中心 (CDC) 表示，流感疫苗对慢性病患者、老年人和孕妇至关重要，应每年接种。根据 CDC 的建议，成年人应接种一剂 Tdap（破伤风、白喉、百日咳）疫苗以预防百日咳。成年人每 10 年接种一次破伤风和白喉疫苗。此外，孕妇应在怀孕期间每 27 至 36 週接种一次 Tdap 疫苗。

政府加大对疾病预防的倡议是否会推动成人疫苗市场的成长？

随着各国政府为预防某些疾病和流行病而采取的措施日益增多，全球成人疫苗市场可望大幅扩张。世界各国政府已经意识到疫苗接种对保护公众健康，尤其是成年人健康的重要性。因此，各国正在实施各种计画和倡议，以促进成年人接种疫苗，包括进行公众意识提升宣传活动，以及在医疗保健和旅游等特定行业强制接种疫苗。

各国政府为预防某些疾病和流行病而做出的越来越多的努力预计将推动全球成人疫苗市场的发展。根据国家卫生使命，印度已设定了消除麻疹和德国德国麻疹的目标，因此于2017年透过分阶段宣传活动引入了麻疹-德国德国麻疹(MR)疫苗。 MR宣传活动旨在为约410万名9个月至15岁的儿童接种两剂疫苗，分别在9至12个月和德国麻疹目前德国麻疹常规作为MR疫苗接种的一部分。

总体而言，未来几年全球成人疫苗市场的成长预计将由政府主导的鼓励成人接种疫苗的努力所推动。各国政府将疫苗接种作为公共卫生计画的基石，希望最大限度地减轻疫苗可预防疾病的负担，增强人口免疫力，并保障全球成年人的健康和福祉。

农村和偏远地区缺乏意识将如何影响成人疫苗市场？

全球成人疫苗接种市场的扩张可能面临巨大挑战，因为人们对成人疫苗接种益处的了解有限，尤其是在开发中国家。这种认知的缺乏不仅影响新兴经济体，也影响到那些往往难以获得医疗保健资讯和服务的偏远农村地区。不了解成人疫苗接种必要性的人可能不会寻求或优先考虑建议的疫苗，从而限制了市场的成长。

此外，成人疫苗的前期成本可能会成为推广的障碍，尤其是在医疗资金有限的地区。除了资金障碍外，物流问题也是阻碍全球成人疫苗市场成长的实施障碍。缺乏有效的提醒机制来鼓励接种疫苗，导致人们错失接种疫苗的机会。

透过提高意识、降低价格和简化疫苗供应系统，可以增强全球成人疫苗产业的发展潜力，相关人员可以培养和提升扩大全球成人预防性医疗保健覆盖率的潜力。

目录

第一章全球成人疫苗市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球成人疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球成人疫苗市场（按疫苗）

  • 概述
  • 肝炎
  • 人类乳突病毒
  • 流感
  • 带状疱疹
  • 其他的

6. 全球成人疫苗市场（依疫苗类型）

  • 概述
  • 单价疫苗
  • 多效价疫苗

7. 全球成人疫苗市场（依技术）

  • 概述
  • 活病毒疫苗
  • 灭活病毒/细菌疫苗
  • 类毒素疫苗
  • 重组疫苗
  • 联合疫苗

8. 全球成人疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

9. 全球成人疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Pfizer, Inc.
  • GlaxoSmithKline Plc.
  • Sanofi Pasteur
  • Merck & Co.
  • CSL Limited
  • Johnson & Johnson
  • Medimmune
  • Serum Institute of India
  • AstraZeneca Plc
  • Novartis

第十一章 附录

相关调查

简介目录
Product Code: 37358

Adult Vaccine Market Valuation - 2026-2032

The rising prevalence of infectious diseases such as influenza, hepatitis, and zoster, as well as government programs to raise awareness of the importance of immunization are driving expansion in the adult vaccine market. The global adult vaccine market study offers a comprehensive assessment of the market. The market size surpass USD 17279.87 Million valued in 2024 to reach a valuation of around USD 27750.04 Million by 2032.

In addition to this, the rising increased research into vaccination technologies and growing government funding are enabling the market to grow at a CAGR of 6.10% from 2026 to 2032.

Adult Vaccine Market: Definition/ Overview

Adult vaccines are immunizations designed for individuals aged 18 and older, aimed at preventing infectious diseases and reducing the risk of severe illness, complications, and pathogen transmission. These vaccines can be administered as primary or booster doses to maintain immunity from childhood vaccines.

Some common types of adult vaccines include influenza (Flu), tetanus, diphtheria, and pertussis (Tdap), pneumonia, shingles, human papillomavirus (HPV), hepatitis A and B, measles, mumps, and rubella (MMR), chickenpox, meningococcal, and hepatitis C. Influenza vaccines are recommended annually to protect against seasonal influenza viruses, especially for high-risk groups like older adults, pregnant women, healthcare workers, and individuals with chronic health conditions. Tdap vaccines are given as a booster every 10 years to maintain protection against tetanus, diphtheria, and pertussis.

Pneumococcal vaccines are recommended for adults 65 years and older, as well as younger adults with certain medical conditions, to prevent pneumonia, meningitis, and bloodstream infections caused by Streptococcus pneumoniae bacteria. Herpes zoster vaccines are recommended for adults 50 years and older to prevent shingles, a painful rash caused by the varicella-zoster virus. HPV vaccines are recommended for adults up to age 26 to protect against cervical, anal, and other cancers, as well as genital warts.

Advancements in treatment and prevention strategies, including vaccines for hepatitis A and B, are essential in managing HCV infections and preventing liver-related complications. Vaccination recommendations may vary based on age, health status, occupation, travel history, and other factors, so consulting with healthcare providers or public health authorities is crucial for determining the appropriate vaccine schedule for each individual.

According to the NCBI, vaccine-preventable diseases kill many adults each year in countries such as the United States. Furthermore, according to the Center for Disease Control (CDC), individuals require an influenza vaccine each year since the vaccine is crucial for those with chronic illnesses, the elderly and pregnant women. According to CDC recommendations each adult must be immunized once with the Tdap (Tetanus, Diphtheria, and Pertussis) vaccine to protect against whooping cough if they have not already been immunized. Adults are also given a booster immunization against tetanus and diphtheria every 10 years. Additionally, pregnant women should get immunized with the Tdap vaccination every 27 to 36 weeks of pregnancy.

Will Rise in Government Initiatives Focusing on Prevention of Diseases Drive the Growth of the Adult Vaccines Market?

The global adult vaccinations market is on track for significant development, driven by an increasing number of government efforts aimed at preventing certain diseases and epidemics. Governments around the world are recognizing the importance of vaccination in protecting public health, particularly among adults. As a result countries are implementing a variety of programs and policies to promote adult vaccination, ranging from public awareness campaigns to vaccine mandates in certain industries such as healthcare and tourism.

The growing number of government attempts to avoid specific diseases and epidemics is predicted to drive the worldwide adult vaccines market. According to the National Health Mission, India is committed to the aim of eliminating measles and controlling rubella, hence the Measles Rubella (MR) vaccine was introduced in the country through a phased campaign in 2017. The Measles-Rubella (MR) campaign aims to immunize around 4.1 million children aged 9 months to 15 years with two doses administered at 9-12 months and 16-24 months. The rubella component is now routinely administered as part of the MR vaccination.

Overall, the growth of the global adult vaccines market in the coming years and government-coordinated efforts to encourage adult immunization are projected to drive. By prioritizing vaccination as a cornerstone of public health policy, governments hope to minimize the burden of vaccine-preventable diseases, boost population immunity and protect the health and well-being of adults worldwide.

How will Lack of Awareness among the Rural Areas or Remote Areas Impact Adult Vaccine Market?

The expansion of the global adult vaccination sector may encounter considerable challenges due to a limited understanding of the benefits of adult vaccination particularly in developing countries. This lack of awareness affects not only emerging nations but also isolated and rural communities where access to healthcare information and services is frequently limited. Individuals who do not understand the necessity of adult vaccination may not seek out or prioritize receiving recommended vaccines limiting market growth.

Furthermore, the initial expenses associated with adult immunizations can be a barrier to expansion, especially in places where healthcare funds are limited. In addition to financial hurdles, logistical issues create implementation barriers that hamper the growth of the worldwide adult vaccines sector. The lack of effective reminder mechanisms to encourage people to be vaccinated can lead to missed opportunities for immunization.

The global adult vaccines industry's development potential by raising awareness, lowering prices, and streamlining vaccine delivery systems, stakeholders can help promote and develop the potential to enable greater access to preventive healthcare for adults globally.

Category-Wise Acumens

How the Adult Vaccine Market is divided into Categories based on Specific Disease of Vaccine Targets?

The worldwide adult vaccinations market is divided according to the specific disease that the vaccine addresses. These include varicella (chickenpox), influenza, human papillomavirus (HPV), tetanus, measles, shingles, pneumococcal illness, and others.

Among them, the influenza vaccine category is currently leading, accounting for over 55% of the global market share in 2022. This dominance is projected to continue, with estimates showing the fastest growth rate for this segment in the future years. The broad prevalence of seasonal flu, an acute respiratory illness caused by the influenza virus is a major driver of the demand for adult vaccine .

According to the World Health Organization (WHO), seasonal flu causes over 400,000 fatalities each year, largely owing to respiratory problems. Furthermore, WHO data show that influenza is especially hazardous for persons over 60 in developed countries, underscoring the importance of broad immunization in this age range.

How the Incising Prevalence of Bacterial and Viral Infection will Drive the Multivalent Vaccines Segments?

The global adult vaccinations industry is divided into two sectors based on the type of vaccine used monovalent and multivalent. Particularly, in 2022, the multivalent vaccines segment contributed significantly to the global market share. According to projections, this segment's influence in the market will grow even stronger in the next years. This expected growth over the evaluation period can be linked to a significant increase in bacterial and viral infections found in Asian and Latin American countries, among others, around the world.

The division of the adult vaccinations market into monovalent and multivalent categories highlights the wide range of vaccines available to treat numerous infectious diseases in adults. In recent years, the multivalent vaccines category has emerged as a key driver of industry growth, thanks to its capacity to defend against several infections with a single vaccination formulation. This immunization efficiency is especially beneficial in areas with increased rates of both bacterial and viral illnesses.

Overall, the trajectory of the multivalent vaccines segment's growth in the worldwide adult vaccines business emphasizes the necessity of innovation and adaptation in dealing with changing healthcare concerns. Multivalent vaccinations, which provide broad-spectrum protection against many pathogens, have the potential to play a critical role in advancing public health goals and lowering the global burden of infectious illnesses.

Country/Region-wise Acumens

How does the North America Account for Major Share in Adult Vaccine Market over the Analysis?

The North American region, which commanded a significant 60% share of the worldwide adult vaccines market in 2022, is expected to maintain its dominance in terms of market revenue share between 2023 and 2030. This expected ongoing leadership in the global market can be linked to an increase in the frequency of viral infections among adults particularly in Canada and the United States.

The North American market is predicted to rise significantly due to an increase in viral infections among adults underscoring the importance of vaccination in disease prevention and public health risk reduction. Particularly, the National Institutes of Health (NIH) found that the influenza vaccine alone reduces approximately 90,000 hospitalizations among older persons in the United States each year, emphasizing the relevance of immunization in reducing healthcare expenses.

The US Centers for Disease Control and Prevention (CDC) has published recommendations for adults to get vaccinated against numerous diseases on a regular basis. Tetanus, diphtheria, and pertussis (Tdap) vaccinations, as well as seasonal influenza, are recommended for all adults. The CDC also advises herpes zoster vaccine for people over the age of 50 and pneumococcal vaccination for adults 65 and older.

How Does the European Market Experience Significant Growth in Adult Vaccine Market?

The European adult vaccine industry is predicted to develop significantly, driven by broad immunization recommendations from EU member states. Notably, as of January 2022, roughly 29 out of 30 EU nations had approved influenza vaccination, demonstrating a strong commitment to preventive healthcare measures. Furthermore, 21 EU nations suggest immunization for pneumonia, demonstrating the importance of protecting adults against respiratory illnesses.

These comprehensive vaccination guidelines from EU countries represent a concerted effort to promote adult immunization and prevent vaccine-preventable diseases. By campaigning for immunization against a variety of infectious agents, European countries are taking proactive actions to protect public health and minimize the burden of preventable illnesses in adults.

As EU countries emphasize immunization efforts and increase access to adult vaccines, the region is positioned to become a leading market for adult vaccination, benefiting both individuals and healthcare systems.

Competitive Landscape

The adult vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the adult vaccine market include:

  • Solvay Pharmaceuticals
  • Moderna
  • BioCSL (Seqirus)
  • Aventis Pasteur
  • Sanofi Pasteur
  • Pfizer Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Johnson & Johnson
  • BioNTech
  • Bharat Biotech International Limited
  • Zhifei
  • Wyeth Vaccines
  • AstraZeneca Plc
  • Medimmune
  • Sinovac
  • Baxter International Healthcare Company
  • Chiron Vaccines
  • Serum Institute of India

Latest Developments

  • In August 2022, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) released interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19. This post summarizes those interim suggestions; you can find the complete advice document here. According to SAGE, the Pfizer-BioNTech COVID-19 mRNA vaccine is both safe and efficacious.
  • In August 2020, Novavax and Serum Institute of India inked a license agreement for the manufacturing and sale of their innovative COVID-19 vaccine candidate, NVX-CoV2373, in low- and middle-income countries, including India. This would improve the company's revenue.

Adult Vaccine Market, By Category

  • Vaccine:
  • Varicella
  • Influenza
  • Human Papillomavirus
  • Tetanus
  • Measles
  • Zoster
  • Pneumococcal
  • Vaccine Type:
  • Monovalent Vaccines
  • Multivalent Vaccines
  • Technology:
  • Live Attenuated Vaccines
  • Inactivated Viral/Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
  • End-User:
  • Private Healthcare Firms
  • Government Hospitals
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL ADULT VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ADULT VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ADULT VACCINE MARKET, BY VACCINE

  • 5.1 Overview
  • 5.2 Hepatitis
  • 5.3 Human Papillomavirus
  • 5.4 Influenza
  • 5.5 Zoster
  • 5.6 Others

6 GLOBAL ADULT VACCINE MARKET, BY VACCINE-TYPE

  • 6.1 Overview
  • 6.2 Monovalent vaccines
  • 6.3 Multivalent vaccines

7 GLOBAL ADULT VACCINE MARKET, BY TECHNOLOGY

  • 7.1 Overview
  • 7.2 Live Attenuated Vaccines
  • 7.3 Inactivated Viral/Bacterial Vaccines
  • 7.4 Toxoid Vaccines
  • 7.5 Recombinant Vaccines
  • 7.6 Conjugate Vaccines

8 GLOBAL ADULT VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 The U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 The U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL ADULT VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Pfizer, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 GlaxoSmithKline Plc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Sanofi Pasteur
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Merck & Co.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 CSL Limited
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Johnson & Johnson
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Medimmune
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Serum Institute of India
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 AstraZeneca Plc
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Novartis
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

Related Research